These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8742794)

  • 1. Lysergamides revisited.
    Pfaff RC; Huang X; Marona-Lewicka D; Oberlender R; Nichols DE
    NIDA Res Monogr; 1994; 146():52-73. PubMed ID: 8742794
    [No Abstract]   [Full Text] [Related]  

  • 2. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).
    Brandt SD; Kavanagh PV; Twamley B; Westphal F; Elliott SP; Wallach J; Stratford A; Klein LM; McCorvy JD; Nichols DE; Halberstadt AL
    Drug Test Anal; 2018 Feb; 10(2):310-322. PubMed ID: 28585392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic medication of behavioral effects in rats.
    Sloviter RS; Drust EG; Damiano BP; Connor JD
    J Pharmacol Exp Ther; 1980 Aug; 214(2):231-8. PubMed ID: 6104720
    [No Abstract]   [Full Text] [Related]  

  • 4. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent.
    Nichols DE; Monte A; Huang X; Marona-Lewicka D
    Behav Brain Res; 1996; 73(1-2):117-9. PubMed ID: 8788487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Dowling G; Wallach J; Halberstadt AL
    Drug Test Anal; 2019 Aug; 11(8):1122-1133. PubMed ID: 31083768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Odland AU; Klein AK; Dowling G; Dempster NM; Wallach J; Passie T; Halberstadt AL
    Drug Test Anal; 2020 Jun; 12(6):812-826. PubMed ID: 32180350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational study of lysergic acid derivatives in relation to their hallucinogenic and antiserotonin activities.
    Kumbar M
    NIDA Res Monogr; 1978; (22):374-407. PubMed ID: 101885
    [No Abstract]   [Full Text] [Related]  

  • 8. Psychedelics without hallucinations?
    Service RF
    Science; 2022 Jan; 375(6579):370. PubMed ID: 35084949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysergic acid diethylamide.
    O'Shea B; Fagan J
    Ir Med J; 2001; 94(7):217. PubMed ID: 11693215
    [No Abstract]   [Full Text] [Related]  

  • 10. An electrographic study of d-lysergic acid diethylamide and nine congeners.
    Schweigerdt AK; Stewart AH; Himwich HE
    J Pharmacol Exp Ther; 1966 Mar; 151(3):353-9. PubMed ID: 5938474
    [No Abstract]   [Full Text] [Related]  

  • 11. Ergot and its alkaloids.
    Schiff PL
    Am J Pharm Educ; 2006 Oct; 70(5):98. PubMed ID: 17149427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Problems of psychotoxicology (a review of the literature)].
    Spivak LI; Mil'shteĭn GI
    Voen Med Zh; 1973 Oct; 10():40-4. PubMed ID: 4786146
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molecular modeling of N-isopropyl lisergamides analogous to LSD using molecular mechanics and quantum mechanical calculations].
    Cordero de Troconis MI; Pfaff R; Nichols D
    Acta Cient Venez; 1997; 48(2):85-90. PubMed ID: 9567327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors.
    Westkaemper RB; Glennon RA
    NIDA Res Monogr; 1994; 146():263-83. PubMed ID: 8742803
    [No Abstract]   [Full Text] [Related]  

  • 15. [Differences in the pharmacological effect of hallucinogenic and von-hallucinogenic lysergic acid derivatives (LSD 25, deseril, lysenyl, mesenyl)].
    Votava Z; Podvalová I; Vojtĕchovský M
    Arzneimittelforschung; 1966 Feb; 16(2):220-2. PubMed ID: 6014083
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of lysergic acid diethylamide and bufotenine on performance of trained rats.
    MAHLER DJ; HUMOLLER FL
    Proc Soc Exp Biol Med; 1959; 102():697-701. PubMed ID: 14419947
    [No Abstract]   [Full Text] [Related]  

  • 17. Interactions of metergoline with diazepam, quipazine, and hallucinogenic drugs on a conflict behavior in the rat.
    Commissaris RL; Rech RH
    Psychopharmacology (Berl); 1982; 76(3):282-5. PubMed ID: 6808551
    [No Abstract]   [Full Text] [Related]  

  • 18. Emetic activity of reduced lysergamides.
    Johnson FN; Ary IE; Teiger DG; Kassel RJ
    J Med Chem; 1973 May; 16(5):532-7. PubMed ID: 4718471
    [No Abstract]   [Full Text] [Related]  

  • 19. Hallucinogenic spatial disorientation.
    Cohen LA
    Int J Neuropsychiatry; 1965 Aug; 1(4):347-51. PubMed ID: 4955762
    [No Abstract]   [Full Text] [Related]  

  • 20. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
    Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
    J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.